Article
Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
Neuro-oncology - 1 Jul 2014
Sabha Nesrin, Knobbe Christiane B, Maganti Majula, Al Omar Soha, Bernstein Mark, Cairns Rob, Çako Besmira, von Deimling Andreas, Capper David, Mak Tak W, Kiehl Tim-Rasmus, Carvalho Philippe, Garrett Evelyn, Perry Arie, Zadeh Gelareh, Guha Abhijit, Sidney Croul
Abstract excerpt
BACKGROUND: Grades II and III gliomas have unpredictable rates of progression, making management decisions difficult. Currently, several clinical and radiological characteristics are utilized to predict progression and survival but collectively are suboptimal. METHODS: In this study, we analyzed a set of 108 nonenhancing hemispheric grade II-III gliomas. Demographic variables, including patient age, tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.